Education
About Us
Working with TipRanks
Follow Us
Redcare Pharmacy (DE:RDC)
XETRA:RDC
Top Page
Redcare Pharmacy
(XETRA:RDC)
53Neutral
Positive Factors
Financial Performance
The EBITDA margin showed a significant improvement from the previous quarter's low.
Market Share
The company's market share increased to 0.87%.
Sales Growth
Redcare published strong FY24 results with Rx growth accelerating in Q4, to >140% y/y, and providing FY25 guidance above expectations.
Negative Factors
Growth Investments
Slowing top line momentum coupled with lower margins due to ongoing growth investments, especially in marketing, would be taken negatively.
Profitability
Intensified marketing efforts came at a cost of slightly lower profitability in FY24.
Sales Momentum
The incremental Rx sales of €11m QoQ has slowed however sequentially.
Redcare Pharmacy (RDC) vs. S&P 500 (SPY)
Market Cap
€2.55B
Dividend YieldN/A
Average Volume (3M)93.15K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth31.79%
EPS Growth-241.61%
CountryDE
Employees1,827
SectorHealthcare
Sector Strength50
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.50
Shares Outstanding20,578,390
10 Day Avg. Volume61,345
30 Day Avg. Volume93,148
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€169.60Price Target Upside35.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Redcare Pharmacy Business Overview & Revenue Model
Company DescriptionRedcare Pharmacy NV owns and operates online pharmacies in Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.
How the Company Makes MoneyRedcare Pharmacy generates revenue primarily through the sale of pharmaceutical products and health-related items via its online platform. The company's revenue streams include direct sales of prescription and over-the-counter medications, health supplements, and personal care products. Additionally, RDC may earn income from partnerships with healthcare providers, insurance companies, or pharmaceutical manufacturers, which can involve collaborative marketing efforts, bulk purchasing agreements, or exclusive product offerings. The company's revenue is further supported by value-added services such as subscription models for regular medication deliveries, which encourage customer retention and consistent sales. Operational efficiency and strategic partnerships are key contributors to RDC's profitability, allowing the company to maintain competitive pricing while ensuring quality and compliance.
Redcare Pharmacy Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.37B | 1.80B | 1.20B | 1.06B | 968.06M | Gross Profit |
| 545.78M | 440.38M | 331.79M | 266.53M | 219.53M | EBIT |
| -38.99M | -17.30M | -69.17M | -65.70M | -866.00K | EBITDA |
| -12.83M | 58.18M | -30.64M | -37.41M | 14.66M | Net Income Common Stockholders |
| -45.46M | -12.04M | -77.65M | -74.19M | -16.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 177.56M | 204.16M | 184.00M | 283.46M | 127.89M | Total Assets |
| 1.00B | 1.02B | 729.47M | 783.08M | 536.91M | Total Debt |
| 246.54M | 244.84M | 255.19M | 236.43M | 38.23M | Net Debt |
| 149.65M | 161.06M | 188.75M | -10.61M | -51.88M | Total Liabilities |
| 493.31M | 469.56M | 374.84M | 367.66M | 111.77M | Stockholders Equity |
| 483.98M | 522.19M | 354.63M | 415.41M | 425.14M |
| Cash Flow | Free Cash Flow | |||
| 13.38M | 23.23M | -82.64M | -31.52M | -35.53M | Operating Cash Flow |
| 22.13M | 61.46M | -29.11M | 11.63M | 17.80M | Investing Cash Flow |
| 8.38M | -59.96M | -138.01M | -84.30M | -40.26M | Financing Cash Flow |
| -17.94M | 15.05M | -13.52M | 229.59M | 50.29M |
Redcare Pharmacy Technical Analysis
Negative
124.90
Price Trends
125.23
Negative
124.69
Positive
131.60
Negative
Market Momentum
0.40
Positive
49.09
Neutral
22.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RDC, the sentiment is Negative. The current price of 124.9 is below the 20-day moving average (MA) of 125.28, below the 50-day MA of 125.23, and below the 200-day MA of 131.60, indicating a bearish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 49.09 is Neutral, neither overbought nor oversold. The STOCH value of 22.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:RDC.
Redcare Pharmacy Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
DE:RDC
Redcare Pharmacy
124.90
4.80
4.00%
GB:0P6S
Bayer
23.97
-5.22
-17.88%
GB:0H9X
Fresenius Medical Care AG & Co. KGaA
50.36
11.39
29.23%
GB:0NI1
Rheinmetall
1,694.00
1,166.02
220.85%
GB:0QXN
Zalando
31.50
6.57
26.35%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.